These findings contribute towards understanding the underlying therapeutic and biological processes associated with monoclonal therapy of EGFR and VEGF anti-tumour activities, and identify further potential protein markers that may contribute in assessment of mCRC treatment response. Here, VEGFA is linked to neoplasm.